Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cascadian Therapeutics Inc.

Division of Seattle Genetics Inc.
www.cascadianrx.com

Latest From Cascadian Therapeutics Inc.

Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data

The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.

Clinical Trials Research and Development Strategies

Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising

Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.

Financing Business Strategies

Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

Puma's CEO voiced confidence the biotech's lead asset Nerlynx will be approved in third-line HER2-positive metastatic breast cancer after its Phase III NALA study met co-primary endpoints.

Cancer Clinical Trials

ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics

The combination of Adcetris with chemotherapy improved progression-free and overall survival in peripheral T-cell lymphoma. Filing is expected soon, and approval will help the product reach blockbuster status.

Clinical Trials Cancer
See All

Company Information

UsernamePublicRestriction

Register